Aini Vuorinen

Aini Vuorinen

Auto-generated profile, based on publicly available information

Aini Vuorinen

Proteomics Science Technology Platform, The Francis Crick Institute, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
GBGeorge S. Biggs
George S. Biggs
ECEmma E. Cawood
Emma E. Cawood
AVAini Vuorinen
Aini Vuorinen
WMWilliam J. McCarthy
William J. McCarthy
HWHarry Wilders
Harry Wilders
JBJacob T. Bush
Jacob T. Bush
Identifying pharmacological probes for human proteins represents a key opportunity to accelerate the discovery of new therapeutics. High-content screening approaches to expand the ligandable proteome offer the potential to expedite the discovery of novel chemical probes to study protein function. Screening libraries of reactive fragments by chemoproteomics offers a compelling approach to ligand discovery, however, optimising sample throughput, proteomic depth, and data reproducibility remains a key challenge. We report a versatile, label-free quantification proteomics platform for competitive profiling of cysteine-reactive fragments against the native proteome. This high-throughput platform combines SP4 plate-based sample preparation with rapid chromatographic gradients. Data-independent acquisition performed on a Bruker timsTOF Pro 2 consistently identified ~23,000 cysteine sites per run, with a total of ~32,000 cysteine sites profiled in HEK293T and Jurkat lysate. Crucially, this depth in cysteinome coverage is met with high data completeness, enabling robust identification of liganded proteins. In this study, 80 reactive fragments were screened in two cell lines identifying >400 ligand-protein interactions. Hits were validated through concentration-response experiments and the platform was utilised for hit expansion and live cell experiments. This label-free platform represents a significant step forward in high-throughput proteomics to evaluate ligandability of cysteines across the human proteome.

15 January 2025 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
AVAini Vuorinen
Aini Vuorinen
CKCassandra R. Kennedy
Cassandra R. Kennedy
KMKatherine A. McPhie
Katherine A. McPhie
WMWilliam McCarthy
William McCarthy
JPJonathan Pettinger
Jonathan Pettinger
KRKatrin Rittinger
Katrin Rittinger
Deubiquitinating enzymes (DUBs) are key regulators of cellular homoeostasis, and their dysregulation is associated with several human diseases. The ovarian tumour protease (OTU) family of DUBs are biochemically well-characterised and of therapeutic interest, yet only a few tool compounds exist to study their cellular function and therapeutic potential. Here we present a chemoproteomics fragment screening platform for identifying novel DUB-specific hit matter, that combines activity-based protein profiling with high-throughput chemistry direct-to-biology optimisation to enable rapid elaboration of initial fragment hits against OTU DUBs. Applying these approaches, we identify an enantioselective covalent fragment for OTUD7B, and validate it using chemoproteomics and biochemical DUB activity assays.

1 August 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AVAini Vuorinen
Aini Vuorinen
IWIsabel V.L. Wilkinson
Isabel V.L. Wilkinson
Maria ChatzopoulouMaria Chatzopoulou
Maria Chatzopoulou
BEBen Edwards
Ben Edwards
SSSarah E. Squire
Sarah E. Squire
ARAngela Russell
Angela Russell

10 October 2023 in Cell Reports Physical Science
Verified
Journal Article
Open access
RCRosa Cookson
Rosa Cookson
AVAini Vuorinen
Aini Vuorinen
JPJonathan Pettinger
Jonathan Pettinger
CKCassandra R. Kennedy
Cassandra R. Kennedy
JKJoanna M. Kirkpatrick
Joanna M. Kirkpatrick
JBJacob T. Bush
Jacob T. Bush

25 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
GBGeorge S. Biggs
George S. Biggs
ECEmma E. Cawood
Emma E. Cawood
AVAini Vuorinen
Aini Vuorinen
WMWilliam J. McCarthy
William J. McCarthy
HWHarry Wilders
Harry Wilders
JBJacob T. Bush
Jacob T. Bush
Identifying pharmacological probes for human proteins represents a key opportunity to accelerate the discovery of new therapeutics. High-content screening approaches to expand the ligandable proteome offer the potential to expedite the discovery of novel chemical probes to study protein function. Screening libraries of reactive fragments by chemoproteomics offers a compelling approach to ligand discovery, however, optimising sample throughput, proteomic depth, and data reproducibility remains a key challenge. We report a versatile, label-free quantification proteomics platform for competitive profiling of cysteine-reactive fragments against the native proteome. This high-throughput platform combines SP4 plate-based sample preparation with rapid chromatographic gradients. Data-independent acquisition performed on a Bruker timsTOF Pro 2 consistently identified ∼23,000 cysteine sites per run, with a total of ∼32,000 cysteine sites profiled in HEK293T and Jurkat lysate. Crucially, this depth in cysteinome coverage is met with high data completeness, enabling robust identification of liganded proteins. In this study, 80 reactive fragments were screened in two cell lines identifying >400 ligand-protein interactions. Hits were validated through concentration-response experiments and the platform was utilised for hit expansion and live cell experiments. This label-free platform represents a significant step forward in high-throughput proteomics to evaluate ligandability of cysteines across the human proteome.